Acebilustat (CTX-4430): A Comprehensive Review of its Pharmacology, Clinical Development, and Therapeutic Potential

I. Executive Summary

Acebilustat, formerly known as CTX-4430, is an orally administered small molecule drug designed as an inhibitor of Leukotriene A4 Hydrolase (LTA4H). Its primary pharmacological action is to reduce the biosynthesis of Leukotriene B4 (LTB4), a potent pro-inflammatory mediator, thereby aiming to exert anti-inflammatory effects in various pathological conditions. Initially developed with a focus on cystic fibrosis (CF), Acebilustat garnered Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for this indication. However, despite promising early-phase biomarker data, the pivotal Phase 2 EMPIRE-CF trial (NCT02443688) did not achieve its primary efficacy endpoint related to lung function improvement, although some trends in reducing pulmonary exacerbations were noted in specific patient subgroups. This outcome significantly impacted its development trajectory for CF.

Subsequently, the development focus for Acebilustat has strategically shifted towards lymphedema. This repositioning is strongly supported by preclinical research, notably from Dr. Stanley G. Rockson's group, which has elucidated a critical role for LTB4 in the pathophysiology of lymphedema. Celltaxis LLC, having acquired the assets from the original developer Celtaxsys Inc., is now advancing Acebilustat in this new therapeutic area. The ongoing Phase 2 HEAL study (NCT05203835) is currently evaluating Acebilustat's efficacy and safety in patients with upper extremity lymphedema. The journey of Acebilustat underscores the complexities of drug development, particularly for anti-inflammatory agents, and highlights the challenges faced by the LTA4H inhibitor class in translating mechanistic promise into broad clinical success. The lymphedema program represents a more targeted, mechanism-driven approach for Acebilustat, addressing a significant unmet medical need.

II. Introduction to Acebilustat (CTX-4430)

A. Chemical and Physical Properties

Acebilustat is a specific chemical entity with well-defined properties. Its systematic development and investigation are rooted in its precise molecular characteristics. The compound is identified by the DrugBank ID DB15385 and was formerly known by the investigational code CTX-4430.[1] As a small molecule drug, its Chemical Abstracts Service (CAS) Number is 943764-99-6.[2] The molecular formula for Acebilustat is C29​H27​N3​O4​, corresponding to a molecular weight of 481.5424 g/mol.[3] It is also known by the synonym EP-501.[4]

These fundamental identifiers are crucial for tracking the compound through various databases, regulatory filings, and scientific literature, ensuring unambiguous reference. The classification as a small molecule dictates its potential for oral bioavailability and its general pharmacokinetic profile, distinguishing it from biologic therapies.

Table 1: Acebilustat - Key Drug Information

Property	Detail	References
Name	Acebilustat	2
Former Name	CTX-4430	1
DrugBank ID	DB15385	4
Type	Small Molecule	1
CAS Number	943764-99-6	2
Molecular Formula	C29​H27​N3​O4​	2
Molecular Weight	481.5424 g/mol	3
Synonyms	EP-501	4
Developer (Original)	Celtaxsys, Inc.	1
Developer (Current)	Celltaxis LLC	8
Mechanism of Action	Leukotriene A4 Hydrolase (LTA4H) inhibitor; reduces Leukotriene B4 (LTB4) production	6

B. Historical Context and Rationale for Development

Acebilustat was originally developed by Celtaxsys, Inc. [1], a company focused on novel treatments for inflammatory diseases by modulating innate immunity.[10] The foundational rationale for Acebilustat's development was its ability to inhibit Leukotriene A4 Hydrolase (LTA4H), thereby reducing the production of Leukotriene B4 (LTB4).[6] LTB4 is a powerful pro-inflammatory lipid mediator and a potent chemoattractant for neutrophils, which are key immune cells involved in the inflammatory cascade of numerous diseases.[1]

The initial broad inflammatory focus of Acebilustat's development is evident from the range of conditions considered or investigated by Celtaxsys. While cystic fibrosis (CF) became a primary target due to the well-documented role of LTB4-driven neutrophilic inflammation in CF lung pathology [1], other indications such as acne vulgaris, hidradenitis suppurativa, and potentially bronchiectasis and pulmonary hypertension were also explored or under consideration.[7] This suggests an early strategy based on the general anti-inflammatory properties derived from LTB4 inhibition, aiming to address conditions where excessive neutrophil activity contributes to tissue damage and disease progression. The significant role of LTB4 in recruiting neutrophils and amplifying inflammation provided a strong mechanistic basis for investigating Acebilustat across these varied inflammatory disorders.[6]

III. Pharmacology of Acebilustat

A. Mechanism of Action: Leukotriene A4 Hydrolase (LTA4H) Inhibition

Acebilustat is an orally bioavailable small molecule that functions as a specific inhibitor of the enzyme Leukotriene A4 Hydrolase (LTA4H).[4] LTA4H is a critical enzyme in the arachidonic acid cascade, specifically responsible for the conversion of LTA4 to LTB4.[1] This conversion is the final and rate-limiting step in the biosynthesis of LTB4.[9]

By targeting and inhibiting LTA4H, Acebilustat effectively curtails the production of LTB4.[1] LTB4 is recognized as a highly potent pro-inflammatory lipid mediator. One of its principal roles in the inflammatory process is acting as a powerful chemoattractant and activator for neutrophils.[6] Neutrophils are primary effector cells of the innate immune system, and their excessive recruitment and activation at sites of inflammation can lead to significant tissue damage.

The reduction in LTB4 levels mediated by Acebilustat is therefore intended to produce anti-inflammatory effects. This is primarily achieved by attenuating neutrophil-driven inflammation, which includes reducing the migration of neutrophils to inflamed tissues (chemotaxis) and diminishing their subsequent activation.[9] Consequently, this modulation of neutrophil activity is expected to lessen the collateral tissue damage that often accompanies chronic or excessive inflammatory responses, a common feature in diseases like cystic fibrosis and potentially other inflammatory conditions.[1]

B. Pharmacokinetics and Pharmacodynamics (PK/PD)

Acebilustat is designed for oral administration and has typically been investigated with a once-daily dosing regimen in clinical trials.[1] Pharmacokinetic studies have shown that Acebilustat achieves steady-state plasma concentrations within approximately 7 to 8 days of consistent dosing.[6] An important characteristic is its plasma-to-whole-blood ratio, which is approximately 1.0. This ratio suggests a relatively even distribution between plasma and blood cells, implying that plasma concentrations can serve as a direct correlate for its pharmacodynamic effects within the blood compartment.[6]

Early pharmacodynamic assessments provided encouraging results regarding target engagement. Specifically, a 100 mg oral dose of Acebilustat was found to achieve maximal inhibition of its target enzyme, LTA4H, for the entire 24-hour period between doses.[10] This sustained target engagement is a highly desirable attribute for a once-daily medication, as it suggests that therapeutic levels of enzyme inhibition can be maintained throughout the dosing interval, potentially leading to more consistent downstream effects on LTB4 production and inflammation. The in vitro IC50​ (half-maximal inhibitory concentration) for Acebilustat's inhibition of LTB4 production in human whole blood is approximately 31 ng/mL, which corresponds to about 0.064μM.[3]

A significant aspect of Acebilustat's pharmacokinetic profile, particularly relevant for its use in patient populations often on multiple medications (such as those with cystic fibrosis), is its interaction with drug-metabolizing enzymes. Studies have indicated that Acebilustat does not induce CYP3A4.[15] CYP3A4 is a major enzyme in the cytochrome P450 system responsible for the metabolism of a large number of drugs. The absence of CYP3A4 induction by Acebilustat is advantageous because it reduces the likelihood of drug-drug interactions where Acebilustat might accelerate the metabolism, and thus reduce the efficacy, of co-administered drugs that are substrates of CYP3A4. This was noted as particularly relevant for CF patients who might be taking CFTR modulators like ivacaftor, which are sensitive to CYP3A4 activity.[15] This characteristic simplifies its potential integration into complex therapeutic regimens.

IV. Clinical Development Program

Acebilustat has undergone an extensive clinical development program, investigating its potential across a range of inflammatory conditions. The journey has been marked by initial promise in early phases, followed by challenges in later-stage trials for certain indications, leading to strategic shifts in its development focus.

Table 2: Summary of Key Acebilustat Clinical Trials

Trial ID	Phase	Indication	Key Objective(s)	Status	Brief Outcome Summary	Primary Developer/Sponsor (at time of trial)
NCT01748838	1	Healthy Volunteers	Safety, tolerability of CTX-4430	Completed	Well-tolerated up to 200 mg/day; good PK/PD, 100 mg showed 24h target engagement.	Celtaxsys Aus Pty Ltd.
NCT01944735	1b	Cystic Fibrosis	Safety, PK/PD, biomarker response	Completed	Safe, well-tolerated; 100 mg reduced sputum neutrophils (65%) & elastase (58%).	Celtaxsys, Inc.
NCT03964558	1	Healthy Volunteers	Mass balance, metabolite profile of [14C]-Acebilustat	Completed	No results detailed in provided information.	Celtaxsys, Inc.
NCT02443688	2	Cystic Fibrosis	Efficacy (FEV1), safety, PEx rate	Completed	Failed primary FEV1 endpoint; no significant overall PEx reduction. Trends in PEx reduction in subgroups. Well-tolerated.	Celtaxsys, Inc.
NCT05203835	2	Lymphedema	Clinical impact of LTB4 antagonism, skin thickening	Active, not recruiting (as of Jan 2022) / Ongoing	Trial ongoing; data analysis expected by Jan 2026. Expanded access program active.	Stanford University / Celltaxis LLC
NCT04662060 / NCT04662086	2	COVID-19 (outpatient)	Sustained symptom resolution, viral shedding	Completed	Did not meet primary outcome; 35% (Acebilustat) vs 53% (placebo) symptom resolution (HR 0.6, p=0.07, favoring placebo). No effect on viral shedding.	Stanford University
NCT02385760	2	Acne Vulgaris	Efficacy and safety in moderate to severe facial acne	Completed	Development discontinued; implies lack of compelling positive results.	Celtaxsys, Inc.
N/A	Preclinical/ Discontinued	Hidradenitis Suppurativa	N/A (Development discontinued by Celtaxsys)	Discontinued	N/A	Celtaxsys, Inc.

A. Early Phase Clinical Trials

The initial clinical evaluation of Acebilustat (then CTX-4430) commenced with foundational Phase 1 studies designed to assess its safety, tolerability, and fundamental pharmacokinetic (PK) and pharmacodynamic (PD) properties.

1. Phase 1 Study in Healthy Volunteers (NCT01748838)

This first-in-human (FIH) trial was critical for establishing the initial safety profile of Acebilustat.10 Conducted by Celtaxsys Aus Pty Ltd., the study involved administering orally escalating doses of CTX-4430, up to 200 mg per day for a duration of two weeks, to a cohort of 96 healthy volunteers.10 The primary objectives were to assess safety and tolerability. The results were positive, with Acebilustat being well-tolerated across all tested dose levels.10 Beyond safety, this trial also provided the first human data on Acebilustat's PK/PD profile, which was reported as excellent. Notably, the 100 mg dose demonstrated maximal inhibition of its target enzyme, LTA4H, over the entire 24-hour dosing interval.10 These encouraging findings supported the decision to advance Acebilustat into further clinical development.10

2. Phase 1b Study in Cystic Fibrosis Patients (NCT01944735)

Following the healthy volunteer study, a Phase 1b trial was conducted to evaluate Acebilustat specifically in adult patients with cystic fibrosis (CF).1 This study aimed to assess safety, PK/PD, and, importantly, the response of inflammatory biomarkers relevant to CF lung disease.16 It was a randomized, double-blind, placebo-controlled, dose-escalation trial involving 17 adult CF patients who received either 50 mg or 100 mg of Acebilustat orally, once daily, for 15 days.14

The study confirmed that Acebilustat was safe and well-tolerated in this patient population.14 Crucially, it demonstrated significant on-target pharmacodynamic effects. Treatment with the 100 mg dose of Acebilustat led to a 65% reduction in sputum neutrophil counts compared to baseline.11 Furthermore, a 58% reduction in sputum neutrophil elastase, a key enzyme implicated in CF lung damage, was observed in the combined treated groups versus placebo.1 Reductions were also noted in other inflammatory markers, including serum C-reactive protein (CRP) and sputum neutrophil DNA.6 Importantly, these anti-inflammatory effects were achieved without adverse trends in lung function or changes in sputum bacterial load, suggesting that the drug did not compromise the ability to control infection.11

3. Phase 1 Mass Balance Study (NCT03964558)

To further characterize the drug's disposition, an open-label, single-dose, single-period Phase 1 study was conducted.18 Its purpose was to assess the mass balance recovery, metabolite profile, and identification of metabolites of [14C]-labeled Acebilustat in healthy male subjects. This trial has been completed, though specific results were not detailed in the provided information.18 Such studies are standard in drug development to understand how a drug is absorbed, distributed, metabolized, and excreted (ADME).

The early phase clinical trials for Acebilustat provided a solid foundation for its continued development. The consistent demonstration of safety and tolerability in both healthy volunteers and CF patients was a critical first step. More significantly, the Phase 1b study in CF patients (NCT01944735) offered promising early signals of biological activity. The observed reductions in key inflammatory biomarkers, such as sputum neutrophil counts and neutrophil elastase, indicated that Acebilustat was engaging its target (LTA4H) and modulating the downstream inflammatory pathways as intended.[6] This biomarker-guided approach, where early human studies incorporate measures of target engagement and biological response, reflects a modern drug development strategy. The positive biomarker data, particularly the reduction of neutrophil elastase which is strongly associated with CF lung disease progression, likely provided substantial encouragement to Celtaxsys to invest in larger and more resource-intensive Phase 2 trials, with cystic fibrosis being the primary focus at that stage.

B. Investigation in Cystic Fibrosis (CF)

The development of Acebilustat for cystic fibrosis was underpinned by a strong pathophysiological rationale targeting the chronic and excessive lung inflammation characteristic of the disease.

1. Pathophysiological Rationale: LTB4 in CF Lung Inflammation

Cystic fibrosis lung disease is defined by a persistent and exaggerated inflammatory response, predominantly driven by neutrophils.12 Leukotriene B4 (LTB4) plays a central role in this process. It is a potent chemoattractant that recruits neutrophils to the airways and an activator that promotes their degranulation and release of damaging substances, including neutrophil elastase.1 Studies have consistently shown that LTB4 levels are significantly elevated in the airways of individuals with CF.19 These elevated LTB4 concentrations correlate with the degree of neutrophilic inflammation, reduced pulmonary function (e.g., FEV1), and overall disease severity.21 Given this direct link between LTB4 and the harmful neutrophilic inflammation in CF, the inhibition of LTB4 synthesis via LTA4H blockade by Acebilustat was hypothesized to reduce this inflammation, thereby potentially slowing lung function decline and reducing the frequency of pulmonary exacerbations.9

2. The EMPIRE-CF Study (NCT02443688): Phase 2

The EMPIRE-CF study was a pivotal Phase 2 trial designed to evaluate the efficacy, safety, and tolerability of Acebilustat in adult CF patients.1 This multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled approximately 199-200 adult patients (aged 18-30 years) with mild-to-moderate lung disease, defined by a percent predicted FEV1 (ppFEV1) of ≥50%, and a history of at least one pulmonary exacerbation in the preceding year.23 Participants received either Acebilustat 50 mg, Acebilustat 100 mg, or placebo orally once daily for 48 weeks, in addition to their existing standard-of-care therapies.1 The study design incorporated stratification based on concomitant use of CFTR modulator therapies, baseline ppFEV1 (categorized as 50-75% and >75%), and the number of pulmonary exacerbations in the year prior to enrollment (1 or >1).19

The co-primary endpoints were the absolute change from baseline in ppFEV1 at week 48 and safety outcomes.[19] Secondary endpoints included the rate of pulmonary exacerbations, time to first pulmonary exacerbation, changes in body mass index (BMI), quality of life as measured by the respiratory domain of the Cystic Fibrosis Questionnaire-Revised (CFQ-R), and various biomarkers of inflammation and infection.[19]

• Efficacy Results:
• ppFEV1: The EMPIRE-CF trial did not meet its primary efficacy endpoint for lung function. There was no statistically significant difference in the change from baseline in ppFEV1 at week 48 between the combined Acebilustat groups (or individual dose groups) and the placebo group.[5] The adjusted mean absolute change from baseline in ppFEV1 at Week 48 was -2.53 percentage points in the combined Acebilustat arms versus -2.69 percentage points in the placebo arm.[19] This lack of effect on FEV1 was a significant setback.
• Pulmonary Exacerbations (PEx): Overall, Acebilustat did not demonstrate a statistically significant reduction in the rate of pulmonary exacerbations compared to placebo.[19] However, Celtaxsys and some investigators highlighted numeric trends towards a reduction in PEx frequency (a reported 19% reduction per protocol assessment) and an increased time to the next exacerbation (a 22% reduced risk per protocol assessment) in patients treated with Acebilustat.[5]
• Subgroup Analyses: Exploratory analyses of pre-specified subgroups suggested potential benefits, although these were not statistically significant for the overall population. For instance, in patients with milder lung disease at baseline (ppFEV1 >75%), a 35% relative reduction in the PEx rate was observed in the combined Acebilustat groups compared to placebo [19], with some reports citing a 34% reduction and a 43% reduced risk of first exacerbation.[25] Similarly, among patients receiving concomitant CFTR modulator therapy, a 20% numeric reduction in the PEx rate was noted with Acebilustat.[19] These subgroup findings, while highlighted by the company, must be interpreted with caution due to the trial failing its primary endpoint and the inherent limitations of subgroup analyses.
• Inflammatory Biomarkers: Contrary to the promising Phase 1b results, the 48-week EMPIRE-CF study did not show significant differences in key inflammatory biomarkers or sputum bacterial densities between Acebilustat-treated subjects and placebo.[19]
• Safety and Tolerability Profile: Acebilustat was generally well tolerated throughout the 48-week study, consistent with earlier phase trials.[19] Most adverse events (AEs) were mild or moderate in severity. Common AEs reported included infective pulmonary exacerbations of CF (the most common AE overall), cough, hemoptysis, and headache.[19] Importantly, there was no increased risk of infection associated with Acebilustat treatment.[25] The rate of discontinuation due to AEs was low and comparable between the Acebilustat and placebo groups.[19] No deaths occurred during the study.[19]
• Overall Outcome and Interpretation: The EMPIRE-CF trial ultimately failed to demonstrate a statistically significant benefit for Acebilustat on its primary lung function endpoint (FEV1) or on the overall rate of pulmonary exacerbations.5 This outcome was a significant disappointment, especially given the promising biomarker responses seen in the shorter Phase 1b study. The disconnect between early biomarker modulation (e.g., neutrophil elastase reduction in Phase 1b) and the lack of sustained clinical benefit in Phase 2 underscores a persistent challenge in CF drug development: translating acute changes in inflammatory markers into long-term, meaningful improvements in clinical outcomes like FEV1. The complex, multifactorial nature of CF lung disease progression likely means that targeting a single inflammatory mediator, even one as central as LTB4, may not be sufficient to alter the disease course significantly, or that FEV1 may not be the most sensitive endpoint for such an intervention over a 48-week period. Celtaxsys's emphasis on the subgroup analyses showing trends in exacerbation reduction, particularly in patients with milder lung disease or those on CFTR modulators, represented an attempt to identify a potential path forward.5 However, such findings are generally considered hypothesis-generating and would require confirmation in new, prospectively designed trials. The context of CFTR modulator use is also noteworthy; while Acebilustat showed a numeric trend towards PEx reduction in this subgroup, the persistence of inflammation even with effective CFTR modulation 13 suggests that complementary anti-inflammatory therapies are still needed, though Acebilustat did not definitively prove to be that solution in this trial. The full results were published by Elborn JS et al. in the Journal of Cystic Fibrosis in 2021.13 No specific long-term follow-up publications extending beyond the 48-week trial results are detailed in the available information.19

3. Regulatory Status: Orphan Drug Designation (FDA, EMA)

In recognition of the significant unmet medical need in cystic fibrosis, a rare disease, Acebilustat received Orphan Drug Designation for its treatment from both the U.S. Food and Drug Administration (FDA) in 2015 and the European Medicines Agency (EMA) in 2014.3 This designation provides various development incentives, such as market exclusivity and fee reductions, to encourage the development of drugs for rare conditions.

C. Investigation in Lymphedema

Following the setbacks in cystic fibrosis, the development focus for Acebilustat pivoted towards lymphedema, an indication with a strong, distinct pathophysiological rationale implicating LTB4, largely driven by the research of Dr. Stanley G. Rockson.

1. Pathophysiological Rationale: LTB4 in Lymphedema (Contributions of Dr. Stanley G. Rockson)

Groundbreaking research from Dr. Stanley G. Rockson's laboratory at Stanford University has been instrumental in identifying LTB4 as a key pathogenic mediator in lymphedema.27 Lymphedema, characterized by chronic swelling due to impaired lymphatic drainage, involves significant tissue inflammation.29 Dr. Rockson's work demonstrated that LTB4, an inflammatory lipid mediator, is found at elevated concentrations in lymphedematous tissues.28 These high levels of LTB4 contribute to the characteristic features of the disease, including sustained inflammation, impaired lymphatic vessel function, and, critically, the inhibition of lymphangiogenesis (the formation of new lymphatic vessels) at these pathological concentrations.28

Interestingly, LTB4 exhibits a bimodal effect on lymphatic endothelial cells (LECs): at lower, perhaps more physiological concentrations, it can promote LEC sprouting and growth, suggesting a role in initial repair. However, at the higher concentrations observed in established lymphedema, LTB4 becomes detrimental, inhibiting lymphangiogenesis and inducing apoptosis in LECs.28 This inhibitory effect is thought to be mediated, at least in part, through the suppression of key signaling pathways crucial for lymphatic health, such as Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Notch signaling.28 Preclinical studies in murine models of lymphedema showed that antagonizing LTB4 signaling could reverse edema, improve lymphatic function, and restore normal lymphatic architecture.28 This targeted, mechanism-driven approach, moving from specific preclinical findings directly implicating LTB4 in lymphedema to clinical investigation with an LTB4 synthesis inhibitor like Acebilustat, represents a focused strategy.

2. The HEAL Study (NCT05203835): Phase 2

Based on this compelling preclinical rationale, the "HEAL" (Helping Ease Arm Lymphedema) study, officially titled "A Pilot Placebo-Controlled Trial of Acebilustat (CTX-4430) for the Treatment of Human Upper Extremity Lymphedema," was initiated.5 This Phase 2 trial is designed to evaluate the efficacy and safety of Acebilustat in patients with unilateral upper extremity lymphedema, typically International Society of Lymphology (ISL) Stage II.33 The study is sponsored by Stanford University, with Celltaxis LLC, the current developer of Acebilustat, providing the drug.8 Dr. Stanley G. Rockson serves as the lead investigator.8

The trial aims to enroll approximately 70 participants.34 It features a blinded, placebo-controlled design where participants receive treatment for 9 months: 3 months of placebo and 6 months of active Acebilustat, though the sequence and blinding details ensure neither participant nor investigator knows the assignment during the treatment period.32 Key inclusion criteria include adults aged 18-75 with unilateral Stage II chronic arm lymphedema of at least 6 months duration and a limb volume ratio (affected to unaffected) of ≥1.2 (or ≥1.1 with specific imaging/history).32

The primary objective is to assess the clinical impact of LTB4 antagonism through oral Acebilustat administration on unilateral upper extremity lymphedema.33 A key secondary objective is to evaluate the impact of Acebilustat therapy on skin thickening, a common and problematic feature of lymphedema, often measured by caliper skinfold quantitation.33 Other assessments include dermal ultrasound, collection of blood samples for biomarkers, and patient-reported quality of life measures.33

• Current Status and Timeline: As of early 2022, the trial was listed as active but not recruiting.[32] Enrollment was reported to have begun in August 2022.[34] In patient forum responses attributed to Dr. Rockson, dated May 2025 [37], it was stated that the trial is "progressing marvelously," with hopes to complete data analysis by January 2026. An earlier comment from October 2024 mentioned an Acebilustat webinar update scheduled for January (presumably January 2025).[37]
• Expanded Access Program: Dr. Rockson also mentioned that an expanded access program (EAP) for Acebilustat in lymphedema is "progressing beautifully" and that results from this program might be published by the end of the year of his comment (likely referring to 2025 or 2026, depending on the specific comment context).[37] The existence of an active EAP during an ongoing Phase 2 trial is noteworthy. While EAPs are generally for serious conditions with no satisfactory alternatives, their active use alongside a Phase 2 trial can sometimes suggest promising early signals or reflect a very high unmet medical need that compels early access considerations by regulatory authorities and sponsors.

The lymphedema program for Acebilustat is strongly supported by patient advocacy groups like the Lymphatic Education & Research Network (LE&RN) [8], underscoring the significant unmet need in this often "ignored indication".[34] This collaborative effort between academic researchers, a focused pharmaceutical company, and patient advocates aims to bring a potentially first-in-class pharmacological treatment to a debilitating chronic condition.

D. Investigation in COVID-19

During the COVID-19 pandemic, there was widespread interest in repurposing existing drugs with anti-inflammatory or antiviral properties to combat the novel coronavirus SARS-CoV-2. Acebilustat, with its known anti-inflammatory mechanism, was evaluated in this context.

1. The COPPS Study (NCT04662060 / NCT04662086): Phase 2

Acebilustat was included as an investigational arm in the COVID-19 Outpatient Pragmatic Platform Study (COPPS).5 This was an adaptive, Phase 2, blinded, randomized, placebo-controlled platform trial designed to efficiently evaluate various therapeutics for outpatients with mild-to-moderate COVID-19.41 The study was sponsored by Stanford University.2 Participants in the Acebilustat arm received 100 mg of the drug orally per day for 28 days, compared to a placebo group.5 The study population largely consisted of vaccinated individuals (90%) and was considered low-risk.5

The primary outcome for the Acebilustat sub-protocol was sustained symptom resolution through day 28.[5] Secondary outcomes included the time to first symptom resolution, the area under the curve (AUC) for longitudinal daily symptom scores, duration of viral shedding through day 10, and symptoms at day 120.[5]

• Results: The trial enrolled 60 participants in the Acebilustat arm and 60 in the placebo arm.[5] Acebilustat did not meet the primary outcome. Sustained symptom resolution by day 28 was achieved by 35% of participants in the Acebilustat arm, compared to 53% in the placebo arm (Hazard Ratio 0.6; 95% Confidence Interval [CI] 0.34-1.04; p=0.07), indicating a trend favoring placebo.[5] There was no significant difference in the mean AUC for symptom scores between the groups. Furthermore, Acebilustat did not demonstrate any effect on viral shedding or on symptoms reported at day 120.[5] The study concluded that sustained symptoms through day 28 were common in this low-risk outpatient population, and Acebilustat did not provide a benefit.[5]

The negative outcome of the COPPS trial for Acebilustat suggests that its broad LTB4-mediated anti-inflammatory action was not beneficial, and perhaps even slightly unfavorable, in the context of mild-to-moderate COVID-19 in a largely vaccinated outpatient population. This could be due to LTB4 not being a critical pathogenic mediator in this specific disease stage or patient group, or that the timing or nature of the intervention was not optimal. It also highlights the challenges of drug repurposing, where a mechanism effective in one chronic inflammatory setting may not translate to an acute viral illness, even one with an inflammatory component.

E. Discontinued and Other Investigated Indications

Prior to its focused development for cystic fibrosis and later lymphedema, Acebilustat (as CTX-4430) was explored or considered for several other inflammatory conditions, largely reflecting its broad LTB4 inhibitory mechanism.

1. Acne Vulgaris (NCT02385760)

Acebilustat was investigated in a Phase 2 clinical trial for the treatment of moderate to severe facial acne vulgaris.2 This was a multi-centre, double-blind, randomized, parallel-group, placebo-controlled efficacy and safety study (NCT02385760).18 The trial has been completed.7 However, development for acne vulgaris was subsequently discontinued by Celtaxsys.7 While specific efficacy results from this trial are not detailed in the provided information, the discontinuation strongly implies that the study did not yield sufficiently compelling positive findings to warrant further investment for this indication.

2. Hidradenitis Suppurativa (HS)

Hidradenitis suppurativa, a chronic inflammatory skin disease, was also listed as an indication for which development of Acebilustat was discontinued by Celtaxsys.7 Although LTB4 accumulation has been noted in HS lesions, suggesting a potential therapeutic rationale 20, no specific preclinical or clinical trial data for Acebilustat in HS are available beyond its discontinuation. It is noteworthy that LYS006, a newer-generation LTA4H inhibitor, is currently being investigated for HS 21, indicating continued interest in this target for the condition.

3. Other Reported Indications

Information from AdisInsight indicated that for conditions such as bronchiectasis, pulmonary hypertension, and skin disorders (as a general category), there was "No development reported" under Celtaxsys for Acebilustat.7 Rosacea was another skin condition for which development was listed as "Discontinued".7

The pattern of discontinuation or lack of reported advancement for these varied inflammatory conditions (acne, HS, rosacea, bronchiectasis, pulmonary hypertension) by the original developer, Celtaxsys, mirrors the challenges faced in the CF and COVID-19 programs. It suggests that while LTB4 inhibition is a mechanistically plausible anti-inflammatory strategy, Acebilustat did not consistently translate this into robust clinical efficacy across these diverse and complex diseases. This may be due to various factors, including the specific role and redundancy of LTB4 pathways in each disease, disease heterogeneity, or the possibility that the achieved level of LTB4 inhibition was insufficient to overcome other pathogenic drivers in these particular conditions.

Table 3: Acebilustat Development Status by Indication

Indication	Highest Phase Reached	Key Trial(s) NCT ID(s)	Outcome / Current Status (as per available info)	Developer(s) Involved
Cystic Fibrosis	Phase 2	NCT02443688 (EMPIRE-CF)	Failed primary FEV1 endpoint; no significant overall PEx reduction. Trends in PEx in subgroups. Orphan Drug status (FDA, EMA). Development for CF not actively pursued by current developer.	Celtaxsys, Inc.
Lymphedema (Upper Extremity)	Phase 2	NCT05203835 (HEAL Study)	Ongoing; active, not recruiting (as of Jan 2022). Data analysis expected by Jan 2026. Positive investigator comments on progress. Expanded access program active.	Stanford University / Celltaxis LLC
COVID-19 (Outpatient)	Phase 2	NCT04662060 / NCT04662086 (COPPS)	Completed. Did not meet primary outcome for symptom resolution (trend favored placebo). No effect on viral shedding.	Stanford University
Acne Vulgaris	Phase 2	NCT02385760	Completed. Development discontinued.	Celtaxsys, Inc.
Hidradenitis Suppurativa	Preclinical/Phase 2 (Discontinued)	N/A	Development discontinued.	Celtaxsys, Inc.
Bronchiectasis	No Development Reported	N/A	No development reported.	Celtaxsys, Inc.
Pulmonary Hypertension	No Development Reported	N/A	No development reported.	Celtaxsys, Inc.
Rosacea	Discontinued	N/A	Development discontinued.	Celtaxsys, Inc.

V. Comparative Analysis: Acebilustat in the LTA4H Inhibitor Landscape

Acebilustat belongs to the class of Leukotriene A4 Hydrolase (LTA4H) inhibitors. Understanding its position within this class requires an overview of other LTA4H inhibitors and the general challenges faced in their development.

A. Overview of LTA4H Inhibitors in Clinical Development

LTA4H has long been considered an attractive therapeutic target for a variety of chronic inflammatory diseases due to its pivotal role in producing the pro-inflammatory mediator LTB4.[44] Consequently, numerous pharmaceutical companies have invested in developing inhibitors of this enzyme. Despite these efforts, and the development of several compounds that have reached clinical trials, no LTA4H inhibitor has successfully navigated the full regulatory process to market approval for major widespread indications.[21]

Examples of LTA4H inhibitors that have undergone clinical investigation include:

• Bestatin (Ubenimex): An immunomodulator approved in some countries (e.g., Japan) for certain cancer indications, Bestatin also possesses LTA4H inhibitory activity.[46] It has been studied for its LTB4-lowering effects and was even part of early research into lymphedema treatment before Acebilustat.[22]
• JNJ-40929837: Developed by Janssen, this compound was investigated for asthma but was discontinued due to a lack of sufficient efficacy in Phase 2 trials and concerns about testicular toxicity observed in preclinical studies.[21]
• DG-051 (Amibepistat): Developed by deCODE genetics/Pfizer, DG-051 reached Phase 2a clinical trials for indications like myocardial infarction and stroke before its development was halted.[6]
• LYS006: A newer-generation LTA4H inhibitor developed by Novartis/Lysosomal Therapeutics, LYS006 is described as highly potent and selective. It has completed Phase 1 studies and is reportedly being investigated in Phase 2 trials for conditions including hidradenitis suppurativa, inflammatory acne, ulcerative colitis, and non-alcoholic steatohepatitis (NASH).[21]

B. Comparative Efficacy and Safety Considerations

Direct head-to-head comparisons of Acebilustat with other LTA4H inhibitors are scarce. However, some comparative points can be inferred from available data:

• LTB4 Inhibition Potency: Acebilustat demonstrated a 76% reduction in sputum LTB4 levels at steady state in CF patients.[6] This level of inhibition was reported to be comparable to that of DG-051 (around 70%) but less potent than LYS006, which is claimed to achieve >90% LTB4 inhibition.[6]
• Safety Profile: In CF trials, Acebilustat's adverse event rate (10-28%) was generally comparable to placebo, which contrasted favorably with the known gastrointestinal and renal risks associated with high-dose ibuprofen, another anti-inflammatory agent used in CF.[6] LYS006 is also reported to have a favorable safety profile in Phase 1, with efficient LTB4 reduction achieved at low plasma exposures, suggesting good tolerability.[21]

C. Challenges and Reasons for Limited Success of the LTA4H Inhibitor Class

The clinical development of LTA4H inhibitors has been fraught with challenges, leading to a high attrition rate. Several factors may contribute to this limited success:

• Lack of Efficacy: A primary reason for failure has been insufficient clinical efficacy in the chosen target indications. This was observed with Acebilustat in the EMPIRE-CF trial (failure to improve FEV1) [19] and with JNJ-40929837 in asthma.[21] This suggests that LTB4, while an important mediator, may not be the sole or dominant driver of pathology in all inflammatory conditions, or that its inhibition alone is insufficient to alter the disease course.
• Toxicity: Some LTA4H inhibitors have encountered toxicity issues. For example, JNJ-40929837 was associated with testicular toxicity in preclinical models, contributing to its discontinuation.[49]
• Pharmacokinetic Challenges and Pathway Shunting: For some LTA4H inhibitors, achieving adequate drug exposure at the site of inflammation without systemic side effects can be difficult. Additionally, inhibiting LTA4H might lead to a "shunting" of the LTA4 substrate towards the production of cysteinyl leukotrienes (CysLTs), which are themselves potent pro-inflammatory mediators, particularly in conditions like asthma. This was a concern raised with JNJ-40929837.[49]
• The "Dual Role" of LTA4H: A more nuanced and significant challenge relates to the dual enzymatic functions of LTA4H. Beyond synthesizing the pro-inflammatory LTB4, LTA4H also possesses a peptidase activity that degrades Pro-Gly-Pro (PGP).[49] PGP is a neutrophil chemoattractant, and its degradation by LTA4H is an anti-inflammatory action. Conventional LTA4H inhibitors, by blocking the enzyme, may inhibit both its LTB4-producing activity (desirable) and its PGP-degrading activity (undesirable). This could lead to an accumulation of PGP, which might counteract some of the benefits of LTB4 reduction and contribute to the observed lack of efficacy of some inhibitors.[49] This complex biology suggests that simply inhibiting LTA4H might not yield a straightforward anti-inflammatory outcome if the balance of its dual roles is not favorably managed.

The development of "new-generation" inhibitors like LYS006, which is described as highly potent and selective [21], indicates that the pharmaceutical industry is attempting to learn from past setbacks. While "selectivity" in this context usually refers to specificity for LTA4H over other enzymes, the ideal future LTA4H inhibitor might need to selectively modulate the LTB4 synthesis pathway without adversely affecting (or even while promoting) PGP degradation, if such differential inhibition is biochemically achievable. This remains a significant challenge for the field. Acebilustat, being an earlier generation compound, likely shares some of the limitations inherent to broadly inhibiting LTA4H without addressing this dual functional complexity.

VI. Corporate and Regulatory Trajectory

The development of Acebilustat has been characterized by a notable transition in corporate stewardship, reflecting both the challenges and the enduring perceived potential of the asset.

A. Developer History

1. Celtaxsys Inc.

Celtaxsys Inc., founded in 2005, was the original developer of Acebilustat (CTX-4430).51 The company's mission was to create novel treatments for inflammatory diseases by modulating innate immunity, with Acebilustat as its flagship candidate.10 Celtaxsys secured funding through various rounds, including a significant $40 million Series D financing in 2015, which was complemented by a $5 million grant from the Cystic Fibrosis Foundation Therapeutics (CFFT) specifically to support the Phase 2 trial of Acebilustat in CF.52

In 2013, Celtaxsys underwent a management and operational restructuring to sharpen its focus on the development of CTX-4430 for cystic fibrosis.53 The company progressed Acebilustat through Phase 1 trials and into the Phase 2 EMPIRE-CF study. In August 2018, Celtaxsys reported the topline results of the EMPIRE-CF trial, acknowledging that the study did not meet its primary FEV1 endpoint but highlighting trends in pulmonary exacerbation reduction in certain subgroups.5

Despite these efforts, Celtaxsys Inc. ultimately ceased operations. Its status is listed as "Out of Business," with a deal type indicating this outcome dated October 22, 2020.51 Detailed financial statements for Celtaxsys for the 2018-2019 period or specific SEC filings were not available in the provided information.18

2. Celltaxis LLC

In 2020, Celltaxis LLC was founded in Atlanta, Georgia, by Michael W. Masters, who is also the Founder, Portfolio Manager, and Chief Investment Officer of Masters Capital Management. Mr. Masters serves as the primary investor and CEO of Celltaxis LLC.34 Celltaxis LLC subsequently acquired the assets related to Acebilustat. Patent assignment records show that interest in LTA4H inhibitor patents, including those covering the chemical backbone of Acebilustat, was transferred from Celtaxsys Inc. assignors to Celltaxis LLC on May 14, 2020.57

Celltaxis LLC is a clinical-stage company that is now spearheading the development of Acebilustat, with a strategic focus on conditions involving dysregulated immune responses, most prominently lymphedema.8 This shift in indication is strongly supported by the preclinical research of Dr. Stanley G. Rockson. Celltaxis LLC is collaborating with Dr. Rockson and Stanford University on the ongoing Phase 2 HEAL study (NCT05203835) for upper extremity lymphedema.8

This corporate transition exemplifies a "phoenix phenomenon" often seen in the pharmaceutical industry, where a promising drug asset from a company that has faced setbacks or ceased operations is acquired by a new entity. The new entity, Celltaxis LLC, is leveraging the existing knowledge and intellectual property surrounding Acebilustat but applying it to a new therapeutic area (lymphedema) based on a distinct and compelling scientific rationale, potentially with a different risk-assessment and development strategy.

B. Patent Information

Intellectual property has been a cornerstone of Acebilustat's development and transition between developers. Celtaxsys Inc. had established a patent portfolio around Acebilustat, including composition of matter patents and patents covering its use, for example, in cystic fibrosis (e.g., US patent 9,820,974 B2), with protection extending to 2034 before any potential extensions.58 The company also held patents for second-generation LTA4H inhibitors (e.g., US patents 9,822,106 B2; 9,856,249 B2; and 9,777,006 B2).58

A patent titled "Method of reducing pulmonary exacerbations in respiratory disease patients" (US-10898484-B2) had a first filing date of May 31, 2018.55 Several other patent applications related to "Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase" (e.g., US-20190161437-A1, EP-3551608-A1, CA-3045887-A1), with an original filing date of December 9, 2016, were noted as inactive.55

Crucially, the assignment of interest in key patents, such as US9822106B2 (covering LTA4H inhibitor compositions), to Celltaxis, LLC was recorded on May 14, 2020.57 This transfer of intellectual property was vital for enabling Celltaxis LLC to undertake the further development of Acebilustat for lymphedema. It underscores the enduring value of robust IP in the pharmaceutical sector, allowing promising compounds to find new avenues for development even after initial challenges.

C. FDA Expanded Access Program

The FDA's Expanded Access Program (EAP), sometimes referred to as "compassionate use," allows patients with serious or immediately life-threatening diseases or conditions, who have no comparable or satisfactory alternative therapies, to gain access to investigational drugs outside of clinical trials.59 This requires that the potential patient benefit justifies the potential risks, and that providing the drug will not interfere with ongoing clinical investigations that could support marketing approval.59 An Investigational New Drug (IND) application and Institutional Review Board (IRB) approval are necessary for expanded access.59 While the FDA allows the vast majority of EAP requests it receives to proceed, manufacturers must also agree to provide the drug.62 Data on adverse events from expanded access use are collected and must be submitted to the FDA; however, these data are interpreted with caution in the drug approval process due to the lack of controlled conditions inherent in clinical trials.62

In the context of Acebilustat, Dr. Stanley Rockson has mentioned that an expanded access program for lymphedema patients is "progressing beautifully".37 This suggests that, concurrent with or following the Phase 2 HEAL study, physicians are requesting and patients are receiving Acebilustat for lymphedema outside the formal trial setting. The active EAP for lymphedema, an indication with high unmet medical need, may reflect promising early observations or simply the pressing need for any potential therapeutic options.

VII. Comprehensive Safety and Tolerability Profile

Acebilustat has been evaluated in multiple clinical trials across diverse patient populations and for varying durations, generally demonstrating a consistent and favorable safety and tolerability profile.

• Healthy Volunteers (NCT01748838): In the initial Phase 1 study, oral doses of Acebilustat up to 200 mg/day for two weeks were administered to healthy volunteers and were found to be well-tolerated.[10]
• Cystic Fibrosis Patients:
• Phase 1b (NCT01944735): In adult CF patients receiving 50 mg or 100 mg daily for 15 days, Acebilustat was safe and well-tolerated. No negative trends in lung function were observed, and importantly, bacterial colonization of the lung remained unchanged, suggesting no overt immunosuppression leading to increased infection susceptibility in this short-term study.[11]
• Phase 2 EMPIRE-CF (NCT02443688): Over a 48-week treatment period, Acebilustat was generally well tolerated.[19] The majority of adverse events (AEs) were mild or moderate in severity. Common AEs reported in patients receiving Acebilustat included infective pulmonary exacerbation of CF (which was also the most common AE in the placebo group), cough, hemoptysis, headache, oropharyngeal pain, rhinorrhea, sinus hypersecretion, rash, arthralgia, and diarrhea.[19] The overall AE rate reported in some analyses (10-28%) was comparable to that observed in the placebo group.[6] Critically, there was no increased risk of infection noted with Acebilustat treatment.[25] The rate of discontinuation due to AEs was low and similar to placebo.[19] No deaths were reported during the study.[19]
• COVID-19 Outpatients (COPPS - NCT04662060 / NCT04662086): In the Phase 2 trial evaluating Acebilustat for mild-to-moderate COVID-19, the available information did not highlight any new or unexpected safety signals, despite the drug not showing efficacy.[5]
• Lymphedema (HEAL Study - NCT05203835): Information provided for the ongoing HEAL study, based on prior trial experience, lists potential adverse events such as upper respiratory infection ("cold"), abnormal liver function tests, headache, rash, abdominal pain, diarrhea, nausea, fatigue, and cough, with most anticipated to be mild to moderate in intensity.[36]

A key positive aspect of Acebilustat's safety profile, particularly relevant for its investigation in CF, has been the lack of evidence suggesting it causes significant immunosuppression that would lead to an increased rate or severity of infections. This is a critical consideration for any anti-inflammatory agent intended for chronic use in populations susceptible to infection. The observation in the Phase 1b CF study that bacterial load did not change [11], and the report from the Phase 2 EMPIRE-CF trial that there was no increased risk of infection [25], are important findings. This differentiates Acebilustat from some other potent anti-inflammatory compounds where increased infection risk has been a dose-limiting factor or reason for discontinuation, such as the LTB4 receptor antagonist BIIL 284 BS, whose trial in CF was terminated early due to an increase in pulmonary-related serious adverse events.[13] The consistent safety findings across different studies and patient groups support the continued investigation of Acebilustat, particularly in the current lymphedema program.

VIII. Conclusion and Future Perspectives

A. Summary of Acebilustat's Development Journey

Acebilustat (CTX-4430) embarked on its development journey as a promising oral LTA4H inhibitor, with a clear mechanism aimed at reducing LTB4-mediated inflammation. Early Phase 1 trials in healthy volunteers and cystic fibrosis (CF) patients demonstrated good safety, tolerability, and, importantly, strong on-target pharmacodynamic effects, including significant reductions in neutrophil markers in CF sputum.[6] This initial promise led to its advancement into larger Phase 2 trials, most notably the EMPIRE-CF study (NCT02443688) for cystic fibrosis, an indication for which it received Orphan Drug Designation.[3]

However, the EMPIRE-CF trial did not meet its primary endpoint of improving FEV1, and while numeric trends towards reduced pulmonary exacerbations were observed in certain subgroups, these were not statistically significant for the overall population.[5] This outcome was a major setback for its CF program. Similarly, a Phase 2 trial (COPPS, NCT04662060) investigating Acebilustat for mild-to-moderate COVID-19 also failed to show efficacy.[5] Development for other inflammatory conditions, such as acne vulgaris (NCT02385760) and hidradenitis suppurativa, was discontinued by the original developer, Celtaxsys Inc..[7] These collective results highlight the challenge of translating LTB4 inhibition into broad clinical success across diverse inflammatory diseases.

The corporate trajectory of Acebilustat saw a significant shift when Celtaxsys Inc. ceased operations [51], and the drug's assets were subsequently acquired by Celltaxis LLC in 2020.[34] This transition has given Acebilustat a new lease on life, with a refocused development strategy.

B. Current Standing and Potential in Lymphedema

The current and most promising avenue for Acebilustat is in the treatment of lymphedema. This strategic pivot is strongly underpinned by specific preclinical research, primarily from Dr. Stanley G. Rockson's group at Stanford University, which has identified LTB4 as a key pathogenic driver in lymphedema, contributing to chronic inflammation, lymphatic dysfunction, and impaired lymphangiogenesis.[28] The ongoing Phase 2 HEAL study (NCT05203835), led by Dr. Rockson and sponsored by Stanford University with drug supply from Celltaxis LLC, is evaluating Acebilustat in patients with upper extremity lymphedema.[8]

There is considerable optimism surrounding this indication. Lymphedema represents a significant unmet medical need with no approved pharmacological treatments that address the underlying disease pathology. Investigators, including Dr. Rockson, have expressed positive sentiments about the trial's progress, with data analysis anticipated by early 2026 and an active expanded access program reportedly yielding encouraging experiences.[37] If the HEAL study demonstrates clear clinical benefits, particularly in reducing limb volume and improving skin changes and quality of life, Acebilustat could become a first-in-class therapy for this debilitating condition. The targeted, mechanism-based approach in lymphedema, born from specific pathophysiological insights, may offer a higher probability of success compared to its previous applications in more broadly defined inflammatory diseases.

C. Broader Challenges for LTA4H Inhibitors and Concluding Remarks

The history of LTA4H inhibitors, including Acebilustat, underscores the inherent difficulties in targeting complex inflammatory pathways. While LTB4 is undoubtedly a potent pro-inflammatory mediator, its role can vary significantly across different diseases and even different stages of the same disease. The limited success of the LTA4H inhibitor class to date may be attributed to several factors: redundancy in inflammatory signaling pathways, the challenge of achieving optimal therapeutic concentrations at specific tissue sites without systemic issues, and the complex dual enzymatic nature of LTA4H itself (both LTB4 synthesis and PGP degradation).[49] Inhibitors that non-selectively block both functions of LTA4H might inadvertently counteract their intended anti-inflammatory benefits.

Future success for this drug class may depend on developing more sophisticated inhibitors that can, for instance, selectively target LTB4 synthesis without impairing beneficial LTA4H functions, or by identifying patient populations and disease states where LTB4 is unequivocally a dominant and critical pathogenic driver.

For Acebilustat, its journey is a testament to the iterative nature of pharmaceutical development. While its broad anti-inflammatory promise did not materialize in CF or COVID-19, the strong scientific rationale for its use in lymphedema offers a renewed opportunity. The consistent safety profile demonstrated across multiple trials is a significant asset. The outcome of the HEAL study will be crucial in determining whether Acebilustat can finally translate its LTB4-inhibitory mechanism into a tangible clinical benefit for patients suffering from lymphedema, a field desperately in need of effective pharmacological interventions. Success in lymphedema would not only provide a much-needed therapy but also validate the targeted, mechanism-driven approach to repurposing and redeveloping drug candidates.

Works cited

1. Acebilustat (Formerly CTX-4430) for CF Lung Inflammation | Cystic Fibrosis News Today, accessed June 10, 2025, https://cysticfibrosisnewstoday.com/acebilustat-ctx-4430-cf-lung-inflammation/
2. Acebilustat - MedPath, accessed June 10, 2025, https://trial.medpath.com/drug/72da8a72bc37ab77/acebilustat
3. ACEBILUSTAT - Inxight Drugs, accessed June 10, 2025, https://drugs.ncats.io/substance/J64RI4D29U
4. Acebilustat | C29H27N3O4 | CID 68488178 - PubChem, accessed June 10, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Acebilustat
5. Acebilustat - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 10, 2025, https://synapse.patsnap.com/drug/59426e3f2c1c46ccb3ea5d94f98ca114
6. Buy Acebilustat | 943764-99-6 | BenchChem, accessed June 10, 2025, https://www.benchchem.com/product/b605122
7. Acebilustat - Celtaxsys - AdisInsight - Springer, accessed June 10, 2025, https://adisinsight.springer.com/drugs/800035422
8. Celltaxis - Lymphatic Education & Research Network, accessed June 10, 2025, https://lymphaticnetwork.org/expo/celltaxis
9. Definition of acebilustat - NCI Drug Dictionary, accessed June 10, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/acebilustat
10. Celtaxsys, Inc. Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430 - BioSpace, accessed June 10, 2025, https://www.biospace.com/celtaxsys-inc-announces-successful-completion-of-phase-1-clinical-trial-for-development-of-ctx-4430
11. Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Its Novel Anti-inflammatory Medicine, Oral Acebilustat, Markedly Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in Patients with Cystic Fibrosis (CF) - GlobeNewswire, accessed June 10, 2025, https://www.globenewswire.com/news-release/2016/11/03/1253500/0/en/Celtaxsys-Announces-Publication-of-Clinical-Trial-Results-Demonstrating-Its-Novel-Anti-inflammatory-Medicine-Oral-Acebilustat-Markedly-Reduced-Lung-Inflammation-Without-Increased-R.html
12. Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity - Frontiers, accessed June 10, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00595/full
13. Why don't anti-inflammatories work in cystic fibrosis?, accessed June 10, 2025, https://www.tandfonline.com/doi/pdf/10.1080/17476348.2024.2323189
14. Acebilustat - Cystic Fibrosis News Today, accessed June 10, 2025, https://cysticfibrosisnewstoday.com/acebilustat/
15. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction - PMC, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5351008/
16. Encouraging Phase 1 Trial Results of Anti-inflammatory Oral Treatment for CF Published, accessed June 10, 2025, https://cysticfibrosisnewstoday.com/news/celtaxsys-phase-1-trial-data-of-anti-inflammatory-acebilustat-for-cf-published/
17. Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis - PubMed Central, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5351012/
18. Celtaxsys, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed June 10, 2025, https://synapse.patsnap.com/organization/98469eaed5fe7314a7da9b03298c11b6
19. EMPIRE-CF STUDY: A PHASE 2 CLINICAL TRIAL OF LEUKOTRIENE A4 HYDROLASE INHIBITOR ACEBILUSTAT IN ADULT SUBJECTS WITH CYSTIC FIBROSIS - PubMed Central, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8649042/
20. Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A 4 Hydrolase, accessed June 10, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&source=all&id=W3130664509
21. LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized ..., accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10837484/
22. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis - PMC, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4755340/
23. Phase 2 study of CTX-4430 in people with CF (EMPIRE) (Celtaxsys CTX-4430) - CFF.org, accessed June 10, 2025, https://apps.cff.org/trials/finder/details/384/Phase-2-study-of-CTX-4430-in-people-with-CF-EMPIRE
24. EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics - PubMed, accessed June 10, 2025, https://pubmed.ncbi.nlm.nih.gov/30056216/
25. Results of Phase 2 Trial Showing Improvements in Pulmonary Exacerbations in Cystic Fibrosis | CheckRare, accessed June 10, 2025, https://checkrare.com/results-of-phase-2-trial-showing-improvements-in-pulmonary-exacerbations-in-cystic-fibrosis/
26. Exacerbations In Subjects Research Articles - R Discovery, accessed June 10, 2025, https://discovery.researcher.life/topic/exacerbations-in-subjects/21701697?page=1&topic_name=Exacerbations%20In%20Subjects
27. Stanley G. Rockson, MD | Stanford Medicine, accessed June 10, 2025, https://med.stanford.edu/profiles/stanley-rockson
28. Leukotriene B4 antagonism ameliorates experimental lymphedema - PubMed, accessed June 10, 2025, https://pubmed.ncbi.nlm.nih.gov/28490670/
29. Lymphatic Dysfunction, Leukotrienes, and Lymphedema | Annual Reviews, accessed June 10, 2025, https://www.annualreviews.org/docserver/fulltext/physiol/80/1/annurev-physiol-022516-034008.pdf?expires=1718215622&id=id&accname=guest&checksum=CB9DD780EE2D0BA9D4A2631165DBF3E5
30. Lymphatic Dysfunction, Leukotrienes, and Lymphedema - PMC - PubMed Central, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6434710/
31. Lymphatic Dysfunction, Leukotrienes, and ... - Annual Reviews, accessed June 10, 2025, https://www.annualreviews.org/doi/pdf/10.1146/annurev-physiol-022516-034008
32. Trial of Acebilustat for the Treatment of Upper Arm Lymphedema, accessed June 10, 2025, https://clinicaltrials.stanford.edu/trials/t/NCT05203835.html
33. Acebilustat for the Treatment of Arm Lymphedema - NCI, accessed June 10, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-09343
34. Interview with Michael W. Masters | Lymphatic Education & Research Network, accessed June 10, 2025, https://lymphaticnetwork.org/news-events/interview-with-michael-w-masters
35. Trial of Acebilustat for the Treatment of Upper Arm Lymphedema - Research | Moss Lab | Stanford Medicine, accessed June 10, 2025, https://med.stanford.edu/mosslab/research.html?ctid=NCT05203835&conditionId=8&serviceLineId=&condition=Breast+Cancer&alpha=t
36. Lymphedema Treatment Study, accessed June 10, 2025, https://studypages.com/s/lymphedema-treatment-study-738761/
37. Ask Dr. Stanley Rockson - Lymphatic Education & Research Network, accessed June 10, 2025, https://lymphaticnetwork.org/ask-experts/e/stanley-rockson
38. Ask Experts | Lymphatic Education & Research Network, accessed June 10, 2025, https://lymphaticnetwork.org/ask-experts/e/crc32
39. News, Events, and Symposiums | Lymphatic Education & Research Network, accessed June 10, 2025, https://lymphaticnetwork.org/news-events/category/news-sub
40. COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol - Clinical Trials | Stanford Medicine, accessed June 10, 2025, https://clinicaltrials.stanford.edu/trials/c/NCT04662060.html
41. COVID-19 Outpatient Pragmatic Platform Study (COPPS) - ClinConnect, accessed June 10, 2025, https://clinconnect.io/trials/NCT04662060
42. COVID-19 Outpatient Pragmatic Platform Study (COPPS) - ClinicalTrials.gov, accessed June 10, 2025, https://cdn.clinicaltrials.gov/large-docs/60/NCT04662060/Prot_SAP_000.pdf
43. Acebilustat Completed Phase 2 Trials for Acne Vulgaris Treatment ..., accessed June 10, 2025, https://go.drugbank.com/drugs/DB15385/clinical_trials?conditions=DBCOND0029828&phase=2&purpose=treatment&status=completed
44. Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase | Journal of Medicinal Chemistry - ACS Publications, accessed June 10, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.0c01955
45. What are LTA4H inhibitors and how do they work? - Patsnap Synapse, accessed June 10, 2025, https://synapse.patsnap.com/article/what-are-lta4h-inhibitors-and-how-do-they-work
46. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking - MDPI, accessed June 10, 2025, https://www.mdpi.com/1420-3049/25/12/2871
47. Inhibition of LTA4H by bestatin in human and mouse colorectal cancer - PMC, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6604047/
48. Groundbreaking Lymphedema Treatment Study | George W. Woodruff School of Mechanical Engineering, accessed June 10, 2025, https://www.me.gatech.edu/groundbreaking-lymphedema-treatment-study
49. Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma | Request PDF - ResearchGate, accessed June 10, 2025, https://www.researchgate.net/publication/263898589_Effects_of_JNJ-40929837_a_leukotriene_A4_hydrolase_inhibitor_in_a_bronchial_allergen_challenge_model_of_asthma
50. LTB4 (Leukotrine System) - Akari Therapeutics, accessed June 10, 2025, https://akaritx.com/ltb4-leukotrine-system/
51. Celtaxsys Inc. - BioCentury Company Profiles - BCIQ, accessed June 10, 2025, https://profiles.biocentury.com/companies/celtaxsys_inc
52. Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne | Fierce Biotech, accessed June 10, 2025, https://www.fiercebiotech.com/biotech/celtaxsys-secures-45m-capital-to-fund-novel-anti-inflammatory-phase-2-programs-cystic
53. Biotech restructurings, scale-backs, bankruptcies: January-December 2013 + - BioWorld, accessed June 10, 2025, https://www.bioworld.com/articles/392553-biotech-restructurings-scale-backs-bankruptcies-january-december-2013
54. Celtaxsys, Inc. Restructures Management and Operations; CEO, CTO Out | Fierce Biotech, accessed June 10, 2025, https://www.fiercebiotech.com/biotech/celtaxsys-inc-restructures-management-and-operations-ceo-cto-out
55. Celtaxsys 2025 Company Profile: Valuation, Funding & Investors | PitchBook, accessed June 10, 2025, https://pitchbook.com/profiles/company/51403-96
56. SEC filings - Cellectis, accessed June 10, 2025, https://www.cellectis.com/en/investors/sec-filings
57. US9822106B2 - Inhibitors of leukotriene A4 hydrolase - Google Patents, accessed June 10, 2025, https://patents.google.com/patent/US9822106B2/en=
58. Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines - Lumira Ventures, accessed June 10, 2025, https://www.lumiraventures.com/news/celtaxsys-announces-the-issue-of-four-new-patents-expanding-its-pipeline-of-selective-leukotriene-b4-modulation-anti-inflammatory-medicines/
59. Expanded Access to Investigational Drugs - Institutional Review Board, accessed June 10, 2025, https://irb.utah.edu/guidelines/fda-requirements-guidance/expanded-access-drug/
60. Expanded Access and Right to Try: Access to Investigational Drugs | Congress.gov, accessed June 10, 2025, https://www.congress.gov/crs-product/R45414
61. Expanded Access | Office of Human Research Protections | West Virginia University, accessed June 10, 2025, https://human.research.wvu.edu/expanded-access
62. INVESTIGATIONAL NEW DRUGS FDA Has Taken Steps to Improve the Expanded Access Program but Should Further Clarify How - GAO, accessed June 10, 2025, https://www.gao.gov/assets/690/685961.pdf